GeoVax Labs and VGX International Announce Agreement at the Las Vegas “International Society of DNA Vaccines” Conference

GeoVax’s Dr. Harriet Robinson - a key conference speaker on “the State of the Art Session” VGXI Inc.’s Robert J. Juba – speaker on Manufacturing a High Concentration Multi-Component DNA Vaccine

Las Vegas, NV – December 8, 2008 –

GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, together with VGX International (VGXI), announced today at the International Society of DNA Vaccines Conference, held in Las Vegas, Nevada, the execution of a Master Product Sale Agreement between VGXI and GeoVax, whereby VGXI will manufacture plasmid, namely the JS2-DNA vaccine, for use in GeoVax’s future preventative and therapeutic clinical human trials.

Based on GeoVax’s ongoing research and development, GeoVax plans to phase-in its JS2-DNA vaccine in future human trials, an enhanced DNA version of the present JS7-DNA vaccine, which the company believes will further improve the vaccine’s performance in human trials and possibly yield even stronger results than its already impressive results which were recently reported at conferences held in Cape-town, South Africa and Cambridge, England. GeoVax’s next generation, JS2-DNA vaccine, is planned to be phased-into GeoVax’s human trials in the near future, as it becomes available from its other suppliers and VGXI, a leader in plasmid vaccine development, with its state of the art production facility in The Woodlands, Texas.

“Any time we can achieve even stronger results in these important human trials, it does make sense to use the best technology going forward. Our innovation is what brought us to this level in the first place and we intend to maintain our leadership position, for the good of our shareholders and humanity”, stated Robert McNally, Ph.D., GeoVax’s CEO and President.

“Dr. Harriet Robinson is a true pioneer in the development of DNA vaccines for HIV and other infectious diseases”, said Henry Hebel, Chief Operating Officer of VGXI. “Her work with GeoVax has been instrumental to the advancement of the field, and VGX International is proud to support these efforts. This agreement further solidifies our position as the world’s leading provider of DNA vaccines.”

GeoVax recently announced that its Phase-2a preventative human trial, involving twelve clinical sites across North and South America, is set to start. This JS2-DNA vaccine implementation will have no impact whatsoever on this trial or any other presently ongoing trials. Upon its availability, however, GeoVax plans to phase it in at the earliest opportunity going forward. Regarding GeoVax’s upcoming therapeutic trial, the Company intends to utilize the JS2-DNA vaccine from the start. Sufficient quantities are scheduled to be produced by VGXI and other suppliers to accommodate GeoVax’s initial therapeutic trial needs as well as quantities which will be required for the phase-in program, replacing the JS7-DNA vaccine presently used in the company’s preventative trials.

Cautionary Factors That May Affect Future Results - Materials in this Web site contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements relate to expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," and other words and terms of similar meaning in connection with a discussion of potential future events, circumstances or future operating or financial performance. In particular, these include statements relating to future actions, prospective products or product approvals, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results. Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed, and forward-looking statements may be adversely affected by factors, including general market conditions, competitive product development, product availability, current and future branded and generic competition, federal and state regulations and legislation, manufacturing issues, timing of the elimination of trade buying, patent positions, litigations and investigations. Our actual results may vary materially, and there are no guarantees about the performance or valuation of VGX stock. It is also important to read the disclosure notice contained in many of the individual VGX documents available on this Web site as many contain important information on such cautionary factors as of the date of the individual document. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise. You are advised, however, to consult any further disclosures we make on related subjects in our reports.

About GeoVax Labx, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's AIDS vaccine technology is the subject of 20 issued or filed patent applications. GeoVax AIDS vaccines are designed for use in uninfected people to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also may be effective as therapeutics (treatment of people already infected with the HIV-1 virus). Studies evaluating these vaccines in HIV/AIDS infected individuals are in the planning stage.

GeoVax's core AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University's Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.

GeoVax AIDS vaccines have moved forward in human clinical trials conducted by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The HVTN, funded through a cooperative agreement with the National Institutes of Health (NIH), is the largest worldwide clinical trials program dedicated to the development and testing of AIDS vaccines. Preclinical work enabling evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID, which provided additional support to GeoVax AIDS vaccine development program with a $15 million IPCAVD grant awarded in late 2007. www.geovax.com.

Company Contact:
Bob McNally
Financial Relations Board
Tel. 404.727.0971
E-mail: bmcnally@geovax.com


About VGXI Inc.
VGXI Inc. is a leading manufacturer of DNA plasmids, and its cGMP and non-cGMP products have passed rigorous reviews by several international regulatory agencies. VGXI offers a wide variety of contract manufacturing services to outside client organizations. The Company’s cGMP manufacturing facility in The Woodlands, Texas is a flexible, purpose-built facility used for research, development, and clinical supply. The site includes 500-liter and 100-liter fermentors and incorporates a cost-effective process. VGX International also has initiated a project to build and operate a 3000-liter scale cGMP, DNA plasmid manufacturing facility in Asia.

Company Contact:
Henry Hebel
Vice President, Manufacturing and Operations
Tel. 281.296.7300
Fax 281.296.7333
E-mail: hhebel@vgxii.com
www.vgxii.com

Media Contact:
Melanie Nimrodi, Financial Relations Board
Tel. 312.546.3508
E-mail: mnimrodi@frbir.com

Safe Harbor Statement: All statements in this news release, not statements of historical fact, are forward-looking statements. These statements are based on expectations and assumptions on the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. Risks and uncertainties include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. Certain matters discussed in this news release are forward-looking statements involving certain risks and uncertainties including, without limitation, risks detailed in the Company's Securities and Exchange Commission filings and reports.

* * *